Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
darunavir/ritonavir · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | GSK2248761 with LPV/RTV arm and probes |
| Cohort 2 | EXPERIMENTAL | GSK2248761 with DRV/RTV |
| Name | Type | Description |
|---|---|---|
| darunavir/ritonavir | DRUG | DRV/RTV 600/100mg |
| lopinavir/ritonavir | DRUG | LPV/RTV 400/100mg |
| Midazolam | DRUG | Midazolam 3mg |
| Dextromethorphan | DRUG | Dextromethorphan 30mg |
| Flurbiprofen | DRUG | Flurbiprofen 50mg |
| GSK2248761 | DRUG | NNRTI under investigation |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * Male or female between 18 and 50 years of age inclusive, at the time of signing the infor...
Darunavir is a small molecule drug being studied in healthy subjects and healthy volunteers. It is being investigated in clinical trials for potential use in treating Human Immunodeficiency Virus (HIV) infection. The drug is currently in Phase 1 clinical development.
Darunavir is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and interactions in healthy volunteers.
Darunavir is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The drug is being studied in early-stage clinical trials to assess its safety, tolerability, and drug interactions.
Darunavir has been studied in two completed Phase 1 clinical trials. NCT00867152 evaluated drug interactions with etravirine and either darunavir/ritonavir or lopinavir/ritonavir. NCT00920088 studied drug interactions of darunavir/ritonavir and lopinavir/ritonavir on GSK2248761 pharmacokinetics and CYP450 probe drugs.
Darunavir is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has been studied in clinical trials involving healthy volunteers, but it has not received regulatory approval for any medical use.
Darunavir is a small molecule drug being studied for its potential effects in healthy subjects. The specific molecular target of Darunavir has not been disclosed in the available clinical trial information. The drug is being evaluated for its safety and drug interactions in early-stage trials.